• Glaucoma

Cosopt Generic Name & Formulations

General Description

Dorzolamide HCl 2%, timolol maleate 0.5%; oph soln; contains benzalkonium chloride.

Pharmacological Class

Carbonic anhydrase inhibitor (sulfonamide) + noncardioselective beta-blocker.

See Also

How Supplied

Cosopt—10mL; Cosopt PF—60 (single-use 0.2mL containers)


Cosopt Indications


Open-angle glaucoma or ocular hypertension where β-blocker alone is inadequate.

Cosopt Dosage and Administration

Adults and Children

<2yrs: not recommended. 1 drop twice daily.

Cosopt Contraindications


Asthma or history of asthma. Severe COPD. Sinus bradycardia. 2nd- or 3rd-degree AV block. Overt cardiac failure. Cardiogenic shock.

Cosopt Boxed Warnings

Not Applicable

Cosopt Warnings/Precautions


Mild-to-moderate COPD or bronchospastic disease, or severe renal impairment: not recommended. Hepatic impairment. Surgery. May mask hypoglycemia or thyrotoxicosis. Myasthenia gravis. Discontinue if ocular effects occur. Soft contact lenses (remove, may reinsert 15 minutes after instillation). Discontinue at 1st sign of cardiac failure. Pregnancy (Cat.C). Nursing mothers: not recommended.

Cosopt Pharmacokinetics

See Literature

Cosopt Interactions


Concomitant oral carbonic anhydrase inhibitors or other topical β-blockers: not recommended. May potentiate systemic β-blockers, reserpine, hypoglycemic agents, and mydriatic effects of topical epinephrine. May be potentiated by quinidine. May inhibit renal excretion of basic drugs and promote excretion of acidic drugs. May increase salicylate toxicity (acidosis). Possible conduction defects, left ventricular failure, or hypotension with calcium channel blockers, digoxin. May block epinephrine.

Cosopt Adverse Reactions

Adverse Reactions

Taste perversion; ocular burning, stinging, or itching; conjunctival hyperemia, blurred vision, superficial punctate keratitis; possible systemic effects.

Cosopt Clinical Trials

See Literature

Cosopt Note

Not Applicable

Cosopt Patient Counseling

See Literature